6 recruiting, 3 unknown, 1 active not recruiting. 5 Phase 2, 3 Early Phase 1, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 4, Unknown 1 |
| Early Phase 1 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
| Not applicable | 2 | Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow BCMA CAR-T: new trials by email Literature Review of BCMA CAR-T trials Research Report on BCMA CAR-T
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma Autologous Hematopoietic Stem Cell Transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs - Multiple Myeloma, Newly Diagnosed | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 30 | 2025-08-10 | 2025-08-06 |
| ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia Autologous hematopoietic stem cell transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs - Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-08-10 | 2025-08-06 |
| MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma BCMA CAR-T, GPRC5D/CD3 BiTEs - Multiple Myeloma, Newly Diagnosed | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 60 | 2025-08-10 | 2025-08-06 |
| A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma ESO-T01 - Relapsed/ Refractory Multiple Myeloma | Early Phase 1 | Recruiting | Chunrui Li | 24 | 2025-01-27 | 2025-02-11 |
| The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies CAR-T Autologous T cell injection - Acute Lymphoblastic Leukemia, Lymphoma | Not applicable | Recruiting | Hebei Senlang Biotechnology Inc., Ltd. | 50 | 2022-09-07 | 2025-06-24 |
| Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM Human BCMA Targeted T Cells Injection - Multiple Myeloma | Phase 2 | Recruiting | Hrain Biotechnology Co., Ltd. | 100 | 2022-07-12 | 2022-12-09 |
| To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM Human Derived anti-BCMA CAR-T Injection - Multiple Myeloma | Early Phase 1 | Active not recruiting | Hrain Biotechnology Co., Ltd. | 18 | 2022-02-09 | 2025-01-03 |
| Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma BCMA CAR-T - Multiple Myeloma | Not applicable | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 20 | 2020-06-30 | 2020-09-29 |
| CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma BCMA CAR-T, Fludarabine, Cyclophosphamide - Relapsed or Refractory Multiple Myeloma | Early Phase 1 | Unknown | Hebei Senlang Biotechnology Inc., Ltd. | 50 | 2020-04-01 | 2020-11-13 |
| Study of BCMA CAR-T in Multiple Myeloma Fludarabine, Cyclophosphamide, BCMA CAR-T - Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Henan Cancer Hospital | 10 | 2017-12-08 | 2017-12-29 |
Multiple Myeloma (10) · Bites and Stings (3) · Recurrence (2) · Leukemia, Plasma Cell (1) · Lymphoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hebei Senlang Biotechnology Inc., Ltd. (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · Hrain Biotechnology Co., Ltd. (2) · Chunrui Li (1) · Henan Cancer Hospital (1)
China (10)
Jianmin Luo, PhD&MD (1) · Juan Du, Doctor (1) · Juan Du, Ph.D. (1) · Peihua Lu, PhD&MD (1) · Songfu Jiang, Professor (1) · Yongping Song (1)